- 3.4Impact Factor
- 4.9CiteScore
- 23 daysTime to First Decision
Journal History
| 1994 | The inaugural issue was released by Multimed Inc. Current Oncology was published as a quarterly journal. |
| 2005 | Journal website and peer review system was launched through Open Journal Systems. |
| 2006 | Current Oncology adopted a bimonthly publication schedule. |
| 2008 | Current Oncology was indexed in PubMed and archived in PubMed Central. Current Oncology was indexed in Science Citation Index Expanded (SCIE)—Web of Science (Clarivate Analytics), starting with Volume 15 (Issue 1). |
| 2009 | Current Oncology was indexed in Scopus (Elsevier), starting with Volume 5 (Issue 3). |
| 2011 | Current Oncology received its first Impact Factor of 1.820. |
| 2018 | Current Oncology was indexed in MEDLINE—National Library of Medicine. |
| 2020 | Current Oncology received an updated Journal Impact Factor of 2.257. Current Oncology was published by MDPI from Volume 28, Issue 1 (2021). The Canadian Association of Psychosocial Oncology (CAPO) became affiliated to Current Oncology. |
| 2021 | Current Oncology established the following sections:
The Canadian Association of Medical Oncologists (CAMO), the Canadian Association of General Practitioners in Oncology (CAGPO) and the Cell Therapy Transplant Canada (CTTC) became affiliated to Current Oncology. |
| 2022 | Current Oncology established the following sections:
|
| 2023 | Current Oncology received its 2022 Impact Factor (2.6). |
| 2024 | The Canadian Centre for Applied Research in Cancer Control (ARCC) became affiliated to Current Oncology. -Section Medical Oncology was discontinued. Current Oncology received a new CiteScore (2023) of 3.3. The year 2024 marked the 30th Anniversary of Current Oncology. Current Oncology received an Impact Factor (2023) of 2.8 and now ranks in Q2. |
| 2025 | Current Oncology established the following section:
Current Oncology received its 2024 Impact Factor (3.4), ranked 118/326 in "Oncology". |
Editor-in-Chief
| 2019–2023 | Editor-in-Chief: Prof. Dr. Sharlene Gill |
| 2023–present | Editor-in-Chief: Prof. Dr. Shahid Ahmed |
Section Editor-in-Chief
| 2021–2023 | Section Editor-in-Chief: Dr. Michael T. Halpern for the section on Health Economics |
| 2021–2025 |
Section Editor-in-Chief: Dr. Stephen Yip for the section on Neuro-Oncology |
| 2021–present | Section Editor-in-Chief: Dr. Normand Blais for the section on Thoracic Oncology Section Editor-in-Chief: Dr. Fiona Schulte for the section on Psychosocial Oncology Section Editor-in-Chief: Prof. Dr. Jörg Kleeff for the section on Surgical Oncology Section Editor-in-Chief: Prof. Dr. Vera Ulrike Bacher for the section on Hematology |
| 2022–present | Section Editor-in-Chief: Prof. Dr. Tommaso Martino De Pas for the section on Bone and Soft Tissue Oncology Section Editor-in-Chief: Dr. Pierre Yves Marcy for the section on Head and Neck Oncology Section Editor-in-Chief: Prof. Dr. Gavin Stuart for the section on Gynecologic Oncology Section Editor-in-Chief: Prof. Karen A. Gelmon for the section on Breast Cancer Section Editor-in-Chief: Prof. Dr. Margaret Fitch for the section on Oncology Nursing |
| 2022–2024 | Section Editor-in-Chief: Prof. Dr. Vittorio Gebbia for the section on Medical Oncology |
| 2023–present | Section Editor-in-Chief: Prof. Dr. Sharlene Gill for the section on Gastrointestinal Oncology |
| 2024–present | Section Editor-in-Chief: Prof. Dr. Matthias May for the section on Genitourinary Oncology Section Editor-in-Chief: Prof. Dr. Katrin Scheinemann for the section on Childhood, Adolescent and Young Adult Oncology Section Editor-in-Chief: Prof. Dr. Stuart Peacock for the section on Health Economics |
| 2025–present | Section Editor-in-Chief: Prof. Dr. Emina Emilia Torlakovic for the section on Oncology Biomarkers Section Editor-in-Chief: Dr. Zhiyuan Xu for the section on Neuro-Oncology Section Editor-in-Chief: Dr. Joerg Krueger for the section on Cell Therapy |
Curr. Oncol. - ISSN 1718-7729